Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Botulinum toxin a + TC-3** is a novel **combination drug formulation** for the treatment of interstitial cystitis–bladder pain syndrome (IC/BPS). It consists of **botulinum toxin type A** (BTX-A), a neurotoxin protein that inhibits acetylcholine release to reduce smooth muscle contraction, mixed with **TC-3**, a reverse-thermal gelation hydrogel. This mixture is instilled into the bladder as a liquid, where TC-3 transitions to a gel at body temperature, resulting in prolonged and gradual release of BTX-A for several hours. Preliminary studies show it is **safe and temporally effective** in improving symptoms of IC/BPS for several weeks. The mechanism of action combines the neuromodulatory effects of botulinum toxin a with the sustained-release and protective barrier properties of the hydrogel carrier[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum toxin a + TC-3.